Quarterly ResultMay 14, 2026, 04:02 PM
NuCana NUC-7738 Gets FDA IND Clearance; Cash Runway into 2029
AI Summary
NuCana announced that its anti-cancer medicine NUC-7738 received FDA Investigational New Drug (IND) clearance in April 2026, enabling clinical investigation in the United States, with an initial focus on melanoma. The company also reported its Q1 2026 financial results, with cash and cash equivalents of £21.5 million as of March 31, 2026, which is expected to fund operations into 2029. NuCana continues to advance enrollment for its Phase 2 NuTide:701 expansion study of NUC-7738, with final data anticipated later in 2026, and is exploring additional indications and combination strategies for NUC-7738.
Key Highlights
- NUC-7738 received FDA IND clearance in April 2026, enabling clinical investigation in the US, initially focusing on melanoma.
- Cash and cash equivalents were £21.5 million as of March 31, 2026, down from £24.3 million at December 31, 2025.
- Cash runway is expected to extend into 2029, providing financial flexibility.
- Net loss for Q1 2026 was £3.9 million, compared to £2.5 million for Q1 2025.
- Basic and diluted loss per ordinary share was £0.00 for Q1 2026, compared to £0.02 for Q1 2025.
- Final data from the Phase 2 NuTide:701 expansion study of NUC-7738 is expected later in 2026.
- The company is advancing evaluation of additional indications and combination strategies for NUC-7738.
Price Impact
More from NCNA